Later-Generation Fluoroquinolones for Tuberculosis

Use of later formulations was associated with a significant reduction in mortality.

Drug resistance accounts for a disproportionate number of deaths due to tuberculosis (TB). The use of later-generation fluoroquinolones, such as moxifloxacin and levofloxacin, may represent a step forward, but few data exist regarding their use and effect on mortality.

Now, investigators have analyzed data from a large, multisite prospective cohort study of 834 patients with active TB with suspected drug resistance. Among this group, 6% were resistant to either isoniazid or rifampicin; 18% were resistant to both isoniazid and rifampicin (MDR); 35% were resistant to either a second-line agent or a fluoroquinolone (pre-XDR); 7% were resistant to isoniazid, rifampicin, a second-line agent, and a fluoroquinolone (XDR), and 28% had a fully suscep…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Later-Generation Fluoroquinolones for Tuberculosis

Topics

Reviewing Author